BBP Fact Sheet: Virtus Biotech ETF
Share
$94.51
close, Nov 20, 2026
Over the year to Nov 19, 2026, BBP returned +27.4% in total and charged 0.34% a year.
- 1-year total return
- +25.5%
- to Nov 20, 2026
- Expense ratio
- 0.34%
- a year
- Net assets
- $126m
- on Nov 19, 2026
- Net flow, last 4 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
BBP $12,739 +27.4% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−9.9%
3 months−12.1%
Year to date+18.3%
1 year+25.5%
3 years+93.3%
5 years+92.5%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
CRINETICS PHARMACEUTICALS INC3.34%
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC1.97%
VERASTEM INC1.95%
PRECIGEN INC1.94%
OMEROS CORP1.87%
NUVATION BIO INC1.77%
REGENERON PHARMACEUTICALS1.72%
PROTAGONIST THERAPEUTICS INC1.71%
ACADIA PHARMACEUTICALS INC1.69%
BRIDGEBIO PHARMA INC1.65%
BBP top ten by weight, 19.6% of the fund, of its 67 equity positions, from the holdings filed for Jul 31, 2026.
Facts
Holds 67 stocks in biotech, 10% of its weight in S&P 500 companies · First traded Dec 17, 2014 · Benchmark Its own holdings, as of Jul 31, 2026